Literature DB >> 6736107

Activated cyclophosphamide: an enzyme-mechanism-based suicide inactivator of DNA polymerase/3'-5' exonuclease.

L Bielicki, G Voelcker, H J Hohorst.   

Abstract

DNA polymerase I from E. coli can toxify activated cyclophosphamide (CP) by means of the 3'-5' exonuclease activity associated with the enzyme. Acrolein and an alkylating moiety are released in the process. Preincubation of DNA polymerase I with activated CP for 15-60 min leads to an increasing inhibition of DNA polymerase activity, which can be prevented when preincubation of DNA polymerase I with activated CP is carried out in the presence of 5' AMP, a competitive inhibitor of the 3'-5' exonuclease subsite of the enzyme. This demonstrates that toxification of activated CP by the 3'-5' exonuclease subsite of DNA polymerase is a prerequisite for the inhibition of DNA polymerase activity. The kinetics and the degree of DNA polymerase inhibition suggest that the alkylating moiety rather than acrolein released from activated CP during toxification is responsible for the inhibition of DNA polymerase. DNA polymerase with associated 3'-5' exonuclease activity has also been isolated from eukaryotic cells, and toxification of activated CP by such an enzyme (DNA polymerase delta from rabbit bone marrow) has been shown previously. Thus we suggest that toxification of activated CP by DNA polymerases/3'-5' exonucleases present mainly in proliferating cells might lead to the specific alkylation of macromolecules involved in the cell proliferation process, such as the DNA polymerase subsite of these enzymes and probably also the DNA bound to the enzymes. The relatively high cancerotoxic selectivity and cytotoxic specificity of activated CP could be based on this specific enzyme-mediated alkylation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6736107     DOI: 10.1007/BF01032606

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  15 in total

1.  [Pharmacological characterization of cyclic nitrogen mustard phosphamide esters as cancer therapeutic agents].

Authors:  N BROCK
Journal:  Arzneimittelforschung       Date:  1958-01

2.  A new mammalian DNA polymerase with 3' to 5' exonuclease activity: DNA polymerase delta.

Authors:  J J Byrnes; K M Downey; V L Black; A G So
Journal:  Biochemistry       Date:  1976-06-29       Impact factor: 3.162

3.  Selective inhibition of the polymerase activity of DNA polymerase. I. Further evidence for separate active sites for polymerase and 3' to 5' exonuclease activities.

Authors:  B G Que; K M Downey; A G So
Journal:  Biochemistry       Date:  1979-05-15       Impact factor: 3.162

4.  Enzymatic synthesis of deoxyribonucleic acid. 36. A proofreading function for the 3' leads to 5' exonuclease activity in deoxyribonucleic acid polymerases.

Authors:  D Brutlag; A Kornberg
Journal:  J Biol Chem       Date:  1972-01-10       Impact factor: 5.157

5.  Deactivation of cyclophosphamide (NSC-26271) metabolites by sulfhydryl compounds.

Authors:  J Draeger; G Peter; H J Hohorst
Journal:  Cancer Treat Rep       Date:  1976-04

6.  The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity.

Authors:  H J Hohorst; U Draeger; G Peter; G Voelcker
Journal:  Cancer Treat Rep       Date:  1976-04

7.  Synthesis and preliminary antitumor evaluation of 4-(SR)-sulfido-cyclophosphamides.

Authors:  G Peter; H J Hohorst
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

8.  Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis.

Authors:  J E Low; R F Borch; N E Sladek
Journal:  Cancer Res       Date:  1982-03       Impact factor: 12.701

9.  Does acrolein contribute to the cytotoxicity of cyclophosphamide?

Authors:  E Wrabetz; G Peter; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

10.  Mouse DNA polymerase alpha. Subunit structure and identification of a species with associated exonuclease.

Authors:  Y C Chen; E W Bohn; S R Planck; S H Wilson
Journal:  J Biol Chem       Date:  1979-11-25       Impact factor: 5.157

View more
  4 in total

1.  Ideas and reality in the development of cancer chemotherapeutic agents, with particular reference to oxazaphosphorine cytostatics.

Authors:  N Brock
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

2.  Enhancement of antitumor activity of the oxazaphosphorine cytostatic SUM-IAP by N-methylformamide.

Authors:  G Voelcker
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-03       Impact factor: 4.553

3.  Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture.

Authors:  M Mohrmann; S Ansorge; U Schmich; B Schönfeld; M Brandis
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

4.  Low toxicity cancer chemotherapy by suicide inactivation of DNA polymerase alpha holoenzyme: first results with new thiazolidinyl- and perhydrothiazinyl-ethyl-N-mustard-phosphamide esters.

Authors:  H J Hohorst; L Bielicki; K Müller; G Voelcker
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.